Clinical Trial

Effectiveness of a Virtual Health Management Community (VHMC) for Pre-diabetes in China

Study acronym: VHMC
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
Individuals with prediabetes are at high risk for developing type 2 diabetes mellitus (T2DM) and are therefore prone to serious complications such as stroke, kidney failure, blindness, and lower-limb amputation. Prediabetes can be reversed, and lifestyle modification is considered the most effective intervention for diabetes prevention. However, it is difficult for individuals with prediabetes to maintain long-term healthy lifestyle changes owing to psychological burnout and poor adherence during daily self-management. We developed a novel virtual health management community (VHMC) model based on group interaction management. The purpose of this study is to evaluate whether a virtual health management community-based intervention can improve glycemic control and related health outcomes in adults with prediabetes. Participants in the intervention group will receive lifestyle management support through a virtual health management community, including health education, lifestyle guidance, and group-based interaction delivered via a digital platform. Participants will be randomly assigned to either the virtual health management community intervention group or a usual care control group. The study will follow participants for approximately 6 months. Participants in the intervention group will receive lifestyle management support through a virtual health management community, including health education, lifestyle guidance, and group-based interaction delivered via a digital platform. Participants will be randomly assigned to either the virtual health management community intervention group or a usual care control group. The study will follow participants for approximately 6 months.
Trial Details
NCT Number NCT07338552
Lead Sponsor Third Affiliated Hospital, Sun Yat-Sen University
Conditions Prediabetes
Enrollment 146 participants
Start Date 2025-12-30
Primary Completion 2026-12-30 (estimated)
Study Completion 2026-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-01-14